Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/29002
Full metadata record
DC FieldValueLanguage
dc.date.accessioned2022-10-06T10:47:04Z-
dc.date.available2022-10-06T10:47:04Z-
dc.date.issued2013-06-
dc.identifier.citationŞen, F. vd. (2013). "The impact of PET/CT imaging performed in the early postoperative period on the management of breast cancer patients". Nuclear Medicine Communications, 34(6), 571-576.en_US
dc.identifier.issn0143-3636-
dc.identifier.issn1473-5628-
dc.identifier.urihttps://doi.org/10.1097/MNM.0b013e328360d8ec-
dc.identifier.urihttps://pubmed.ncbi.nlm.nih.gov/23549550/-
dc.identifier.urihttp://hdl.handle.net/11452/29002-
dc.description.abstractObjectives The aim of the study was to evaluate the role of F-18-fluorodeoxyglucose (F-18-FDG) PET/computed tomography (CT) in the early postoperative staging of breast cancer and to document F-18-FDG PET/CT-based stage alterations and any subsequent impact on management. Materials and methods Between January 2009 and June 2012, PET/CT images of patients with histopathologically proven breast cancer who underwent surgery with no previous chemotherapy or radiotherapy were retrospectively reviewed. Any stage alteration due to a change in nodal or metastatic status on PET/CT was noted. Results A total of 77 women (median age: 52 years; range: 26-87 years) were included. PET/CT revealed distant metastases that were previously undetected in 12 of the 77 women (15.6%). Of these women, one (8.3%) was diagnosed with stage I, four (33.3%) with stage II, and seven (58.4%) with stage III disease before the PET study. In two patients, lung lesions were diagnosed as metastases by conventional imaging methods, and in one patient the lesions were revealed to have a low probability for malignancy on PET/CT, and they were confirmed as benign on follow-up CT. Thus, changes in disease stage occurred in 15 of 77 (19.5%) patients following PET/CT. The disease was upstaged in 14 patients (18.2%) and downstaged in one (1.3%). Conclusion The impact of F-18-FDG PET/CT is highest in newly diagnosed stage III breast cancer because of the identification of previously undetected extra-axillary lymph nodes and distant metastases. Early postoperative F-18-FDG PET/CT imaging may alter the staging and potentially contribute to the management of these patients.en_US
dc.language.isoenen_US
dc.publisherLippincott Williams and Wilkinsen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectRadiology, nuclear medicine & medical imagingen_US
dc.subjectF-18-FDG PET/CTen_US
dc.subjectBreast canceren_US
dc.subjectPositron-emission-tomographyen_US
dc.subjectStagingen_US
dc.subjectFDG-PET/CTen_US
dc.subjectManagementen_US
dc.subjectStaging proceduresen_US
dc.subjectMetastasesen_US
dc.subjectNodesen_US
dc.subjectIIBen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 and overen_US
dc.subject.meshBreast neoplasmsen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshMultimodal imagingen_US
dc.subject.meshNeoplasm metastasisen_US
dc.subject.meshNeoplasm stagingen_US
dc.subject.meshPositron-emission tomographyen_US
dc.subject.meshPostoperative perioden_US
dc.subject.meshRetrospective studiesen_US
dc.subject.meshRisk assessmenten_US
dc.subject.meshTime factorsen_US
dc.subject.meshTomography, x-ray computeden_US
dc.titleThe impact of PET/CT imaging performed in the early postoperative period on the management of breast cancer patientsen_US
dc.typeArticleen_US
dc.identifier.wos000329072500009tr_TR
dc.identifier.scopus2-s2.0-84876988344tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Tıbbi Farmakoloji Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-2325-7728tr_TR
dc.identifier.startpage571tr_TR
dc.identifier.endpage576tr_TR
dc.identifier.volume34tr_TR
dc.identifier.issue6tr_TR
dc.relation.journalNuclear Medicine Communicationsen_US
dc.contributor.buuauthorŞen, Feyza-
dc.contributor.buuauthorAkpınar, Ali Tayyar-
dc.contributor.buuauthorOǧur, Ümit-
dc.contributor.buuauthorDuman, Gani-
dc.contributor.buuauthorTamgaç, Feyzi-
dc.contributor.buuauthorAlper, Eray-
dc.contributor.researcheridAAJ-8660-2021tr_TR
dc.identifier.pubmed23549550tr_TR
dc.subject.wosRadiology, nuclear medicine & medical imagingen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubMeden_US
dc.wos.quartileQ3en_US
dc.contributor.scopusid55222520800tr_TR
dc.contributor.scopusid14324350600tr_TR
dc.contributor.scopusid35086740700tr_TR
dc.contributor.scopusid55634006600tr_TR
dc.contributor.scopusid35569192500tr_TR
dc.contributor.scopusid7006827670tr_TR
dc.subject.scopusFluorodeoxyglucose F 18; Positron Emission Tomography Computed Tomography; Breast Neoplasmsen_US
dc.subject.emtreeFluorodeoxyglucose f 18en_US
dc.subject.emtreeAntineoplastic agenten_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeBone metastasisen_US
dc.subject.emtreeBreast canceren_US
dc.subject.emtreeCancer chemotherapyen_US
dc.subject.emtreeCancer patienten_US
dc.subject.emtreeCancer radiotherapyen_US
dc.subject.emtreeCancer stagingen_US
dc.subject.emtreeComparative studyen_US
dc.subject.emtreeComputer assisted emission tomographyen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDistant metastasisen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeFollow upen_US
dc.subject.emtreeHistopathologyen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeLiver metastasisen_US
dc.subject.emtreeLung lesionen_US
dc.subject.emtreeLung metastasisen_US
dc.subject.emtreeLung noduleen_US
dc.subject.emtreeLymph nodeen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMultimodality cancer therapyen_US
dc.subject.emtreePostoperative perioden_US
dc.subject.emtreeProbabilityen_US
dc.subject.emtreeRetrospective studyen_US
Appears in Collections:Scopus
Web of Science

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.